LifeSci Capital LLCGuggenheim Securities, LLCMorgan Stanley & Co. LLCLeerink Partners LLC
Description
On August 19, 2026, Amylyx Pharmaceuticals, Inc. completed an underwriting agreement for the issuance of 14,090,000 shares of common stock at $35.50 per share. The company also granted underwriters an option to purchase additional shares. This funding will support the company’s ongoing development of therapeutics for neurodegenerative diseases.
Who to call at Amylyx Pharmaceuticals, and when
A new round usually means Amylyx Pharmaceuticals is about to hire and buy. The teams that reach out first get the meeting.
An alert the day Amylyx Pharmaceuticals raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Amylyx Pharmaceuticals, from your own LinkedIn network
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
Amylyx Pharmaceuticals
Location
Cambridge, Massachusetts, United States
About
Amylyx Pharmaceuticals, Inc. is committed to supporting and creating more moments for the neurodegenerative disease community through the discovery and development of innovative new treatments. Amylyx is headquartered in Cambridge, Massachusetts and has operations in Canada and EMEA. For more information, visit amylyx.com and follow us on LinkedIn and Twitter. For investors, please visit investors.amylyx.com.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Amylyx Pharmaceuticals raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
CambridgeBiotechnologyHealthcareHealth CareTherapeuticsPharmaceutical